October 26, 2026 · Journal of hepatology · DOI: 10.1016/j.jhep.2026.10.018

Intestinal Candida albicans promotes HCC progression and anti-PD-1 resistance via IL-17A and Trem2+ macrophages.

Listen to this summary

This study asks whether intestinal fungal dysbiosis, specifically Candida albicans, drives hepatocellular carcinoma progression and resistance to immune checkpoint inhibitors. In patients, higher fecal C. albicans was linked to advanced disease, shorter survival, and reduced benefit from ICI therapy, and in mouse models C. albicans gavage promoted tumor growth via an IL-17A-driven circuit that recruits and polarizes immunosuppressive Trem2+ macrophages, suppressing CD8+ T cells. Antifungal treatment and IL-17A blockade attenuated tumor progression and partially restored anti-PD-1 efficacy, suggesting fecal C. albicans and this immune axis may be candidate biomarkers and therapeutic targets, though the human cohorts were modest and the antifungal approach was only tested in mice.

Lilong Zhang, Kunpeng Wang, Dongqi Chai, Tinghui Mo, Wanrong Jiang, Wangbin Ma, Bo Yu, Qiao Shi, Pingan Ding, Wenhong Deng, Weixing Wang, Kailiang Zhao, Chen Chen

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play